| Allan H Daniels, MD | |
|
22710 Professional Dr., Ste#202, Kingwood, TX 77339 | |
| (281) 312-8521 | |
| (281) 359-7971 |
| Full Name | Allan H Daniels |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 27 Years |
| Location | 22710 Professional Dr., Kingwood, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538265905 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | L 2859 (Texas) | Secondary |
| 207R00000X | Internal Medicine | L2859 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kingwood Medical Center | Kingwood, TX | Hospital |
| Memorial Hermann Northeast Hospital | Humble, TX | Hospital |
| Entity Name | Baylor St Lukes Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740485879 PECOS PAC ID: 9133213192 Enrollment ID: O20070920000863 |
News Archive
For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.
Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product.
AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.
A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer.
› Verified 7 days ago
| Entity Name | Texienne Oncology Centers, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700017449 PECOS PAC ID: 7012054281 Enrollment ID: O20091020000492 |
News Archive
For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.
Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product.
AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.
A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer.
› Verified 7 days ago
| Entity Name | East Texas Clinical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326596776 PECOS PAC ID: 8224319983 Enrollment ID: O20170111002911 |
News Archive
For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.
Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product.
AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.
A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer.
› Verified 7 days ago
| Entity Name | David P Ellent Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245777440 PECOS PAC ID: 7012290885 Enrollment ID: O20170202000805 |
News Archive
For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.
Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product.
AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.
A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer.
› Verified 7 days ago
| Entity Name | Daniels Internal Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588315402 PECOS PAC ID: 2769875582 Enrollment ID: O20220131001046 |
News Archive
For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.
Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product.
AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.
A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Allan H Daniels, MD 22710 Professional Dr., Ste#202, Kingwood, TX 77339 Ph: (281) 312-8521 | Allan H Daniels, MD 22710 Professional Dr., Ste#202, Kingwood, TX 77339 Ph: (281) 312-8521 |
News Archive
For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.
Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product.
AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.
A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer.
› Verified 7 days ago
Liza Jemison, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1330 Kingwood Dr, Suite 200, Kingwood, TX 77339 Phone: 281-348-7301 Fax: 281-348-2186 | |
Dr. Mohamed Wael J Khirfan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 24044 Highway 59 N, Kingwood, TX 77339 Phone: 281-674-7812 Fax: 281-310-6602 | |
Dr. Sivatej Sarva, M.B.B.S Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 451 Kingwood Medical Dr Ste 100, Kingwood, TX 77339 Phone: 281-318-2043 Fax: 281-536-6306 | |
Branden Carl Wilson, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 22999 Highway 59 N Ste 105, Kingwood, TX 77339 Phone: 281-348-8934 | |
Dr. Syed Arman Raza, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2627 Chestnut Ridge Dr, Suite 100, Kingwood, TX 77339 Phone: 281-358-1950 Fax: 281-358-3102 | |
Dr. Mary K Crow, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 22710 Professional Dr, Kingwood, TX 77339 Phone: 281-298-8444 Fax: 281-298-7720 | |
Mr. Alexander Tiu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 22999 Highway 59 N, # 214, Kingwood, TX 77339 Phone: 281-359-5010 Fax: 281-359-5131 |